Carlsmed, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CARL | DRIO | AIML.CN | 3733.T | ACARIX.ST | OFIX | |
|---|---|---|---|---|---|---|
| Market cap | 439.30M | 29.10M | 13.43M | 52.33B | 206.92M | 392.90M |
| P/E (TTM) | — | — | — | 10.5 | — | — |
| Forward P/E | -11.7 | -2.7 | — | 10.4 | — | 26.3 |
| Price/book | 5.2 | 0.4 | -6.4 | 1.4 | 4.8 | 0.9 |
| Dividend yield | — | — | — | 1.47% | — | — |
| 1-year change | +35.32% | −75.41% | 0.00% | −17.79% | −33.90% | −33.79% |
| Today | +11.74% | −1.00% | −10.00% | −0.69% | −7.23% | +10.96% |
The closest companies by business and industry (Health Information Services). Prices may be delayed up to 20 min.
Latest news
All CARL news ›Carlsmed launches lumbar spine system at NASS annual meeting
Carlsmed, Inc. (Nasdaq: CARL) announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting in San Antonio, Texas. The launch follows a limited market…
Carlsmed (NASDAQ:CARL) Price Target Raised to $24.00
Carlsmed (NASDAQ:CARL - Get Free Report) had its target price boosted by stock analysts at BTIG Research from $23.00 to $24.00 in a research report issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the stock.…
Carlsmed, Inc. (NASDAQ:CARL) Stock Has Consensus Target Price of $19.25
Get Our Latest Analysis on CARL Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company develops patient-specific implants and digital planning tools intended to help surgeons address…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketbeat.com2
- streetinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.